SCHEMBL1045266

SCHEMBL1045266

COc1cc2c3c(c4c(c2cc1OC)-c1ccccc1C4(C)C)C=CC(c1ccccc1)(c1ccc(N2CCOCC2)cc1)O3

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK10 O94804 1/20 0.35
SLK Q9H2G2 1/20 0.35
PIK3CA P42336 1/20 0.35
ALDH1A1 P00352 4/20 0.35
MAPT P10636 3/20 0.35
KDM4E B2RXH2 2/20 0.35
LMNA P02545 2/20 0.35
NPC1 O15118 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HIF1A Q16665 3/20 0.34
TTK P33981 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
MAPK1 P28482 2/20 0.33
CLK4 Q9HAZ1 2/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29453309 1.00 STK10 (0.35) STK10SLKPIK3CAALDH1A1MAPT
SCHEMBL25605055 0.98 STK10 (0.36) STK10SLKPIK3CAALDH1A1MAPT
SCHEMBL11995963 0.95 PIK3CA (0.35) STK10SLKPIK3CAALDH1A1MAPT
SCHEMBL25605060 0.95 PIK3CA (0.35) STK10SLKPIK3CAALDH1A1MAPT
SCHEMBL13868743 0.95 MAPT (0.35) STK10SLKPIK3CAALDH1A1MAPT
SCHEMBL2200006 0.95 ACHE (0.35) ALDH1A1MAPTLMNASMN1; SMN2MEN1
SCHEMBL25844425 0.94 STK10 (0.35) STK10SLKPIK3CAALDH1A1MAPT
SCHEMBL3707410 0.93 HIF1A (0.34) STK10SLKPIK3CAALDH1A1MAPT
SCHEMBL26513274 0.93 MAPT (0.36) PIK3CAALDH1A1MAPTKDM4ELMNA
SCHEMBL24620699 0.93 ACHE (0.35) STK10SLKALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11874434-B2 Ophthalmic devices comprising photochromic materials with reactive substituents JOHNSON & JOHNSON VISION CARE, INC. (US) 2024-01-16 US disclosed
EP-4270067-A1 PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND GLASSES Hoya Lens Thailand Ltd. (TH) 2023-11-01 EP disclosed
EP-4269532-A1 PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES Hoya Lens Thailand Ltd. (TH) 2023-11-01 EP disclosed
US-20230340318-A1 PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES HOYA LENS THAILAND LTD. (TH) 2023-10-26 US disclosed
US-20230340318-A1 PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES HOYA LENS THAILAND LTD. (TH) 2023-10-26 US disclosed
US-20230227717-A1 PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND SPECTACLES HOYA LENS THAILAND LTD. (TH) 2023-07-20 US disclosed
EP-4198583-A1 PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND SPECTACLES Hoya Lens Thailand Ltd. (TH) 2023-06-21 EP disclosed
US-20220137262-A1 OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS JOHNSON & JOHNSON VISION CARE (US) 2022-05-05 US disclosed
US-11256002-B2 Ophthalmic devices comprising photochromic materials with reactive substituents JOHNSON & JOHNSON VISION CARE, INC. (US) 2022-02-22 US disclosed
EP-3633423-A1 OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS Johnson & Johnson Vision Care, Inc. (US) 2020-04-08 EP disclosed
US-20120156508-A1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL, INC. (US) 2012-06-21 US disclosed
WO-2012082999-A1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL, INC. (US) 2012-06-21 WO disclosed
US-20120156508-A1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL, INC. (US) 2012-06-21 US disclosed
EP-2270559-A2 Ophthalmic devices comprising photochromic materials with reactive substituents Johnson and Johnson Vision Care, Inc. (US) 2011-01-05 EP disclosed
EP-1866699-B1 PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS TRANSITIONS OPTICAL INC (US) 2010-05-05 EP disclosed
US-7556750-B2 Photochromic materials with reactive substituents TRANSITIONS OPTICAL, INC. (US) 2009-07-07 US disclosed
EP-1866699-A1 PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS TRANSITIONS OPTICAL, INC. (US) 2007-12-19 EP disclosed
WO-2006110219-A1 PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS TRANSITIONS OPTICAL, INC. (US) 2006-10-19 WO disclosed
US-20060226401-A1 Ophthalmic devices comprising photochromic materials with reactive substituents JOHNSON & JOHNSON VISION CARE, INC. 2006-10-12 US disclosed
US-20060226400-A1 Photochromic materials with reactive substituents TRANSITIONS OPTICAL LIMITED (IE) 2006-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120156508-A1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS CRY2, CRY1, IPO4 STK10 4021/4885SLK 2064/4885PIK3CA 582/4885
US-20230340318-A1 PHOTOCHROMIC COMPOUND, PHOTOCHROMIC COMPOSITION, PHOTOCHROMIC ARTICLE, AND EYEGLASSES NR2E3, CRY1, RPS10 STK10 1116/4885SLK 2041/4885PIK3CA 3076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.